Healthcare >> Analyst Interviews >> July 28, 2003
RAHUL JASUJA is a Research Analyst at Techvest, LLC. Prior to joining
Techvest, he served as biotechnology Research Analyst for the New York
investment banking firm of Rodman & Renshaw. He conducted equity
research in various areas of molecular medicine, including
immunotherapy, oncology, cardiology and tissue engineering. Previously,
he served as a biopharmaceutical industry analyst at Business
Communications Company Inc., a technology analysis and market research
firm, where he authored reports on numerous biotechnology topics. Dr.
Jasuja received his scientific training in immunology at Tufts Medical
School and Harvard Medical School. He has conducted research in the
areas of cell signaling, cancer biology, T-lymphocyte adhesion and
activation, and macrophage arachidonic acid metabolism. At Tufts Medical
School he taught and supervised medical and dental students in the field
of immunology. Dr. Jasuja received his BSc from St. Xavier's College,
Bombay (India), his MS in Microbiology and Molecular Biology from the
University of Montana and his PhD in Immunology from Tufts Medical
School in Boston. Profile
Dr. Jasuja: Techvest is a boutique biotechnology/medical device
investment banking and equity research firm that has its
